Nurix Therapeutics, INC 8-K filings

Nurix Therapeutics has announced the pricing of an upsized public offering expected to generate $175 million in gross proceeds.

Nurix Therapeutics announced its first quarter fiscal 2024 financial results and provided a corporate update, highlighting extended collaborations with Gilead and Sanofi, and positive clinical data for its lead drug candidate, NX-5948.

Nurix Therapeutics reported encouraging clinical responses in two patients with B-cell malignancies involving the central nervous system, using their novel drug NX-5948.

The FDA has lifted the partial clinical hold on Nurix Therapeutics' Phase 1 trial of NX-2127, allowing the company to resume enrollment with a new, improved drug product.

Nurix Therapeutics announced its fiscal year 2023 financial results, highlighted by significant clinical advancements and $100 million in non-dilutive funding.